BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that the European Medical Agency (EMA) has awarded its Priority Medicines (PRIME)…Read More
Praxis Precision Medicines Inc Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen PRAX222 for Treatment of SCN2A Gain of Function Developmental Epilepsies
